Despite some renal problems Gilead's Quad is promising HIV treatment
This article was originally published in Scrip
Executive Summary
Following the May 8 good news for Gilead Sciences that USFDA staffers found its HIV treatment Truvada (emtricitabine and tenofovir disoproxil fumarate) also safe and effective as a preventative for the disease, the company got the word that the agency analysts have no insurmountable problems with Gilead's next-generation HIV drug: the fixed-dose tablet combining elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate and dubbed Quad.